---
title: Health-Ecore
description: The future of sustainable healthcare depends on integrated, scalable innovation. Let’s build it together.
---

[Skip to the main content.](https://health-ecore.com#main-content)

[![HE\_logo\_fc-35-1](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35-1.png?width=1500&height=326&name=HE_logo_fc-35-1.png "HE_logo_fc-35-1")](https://health-ecore.com/?hsLang=en)

[![Health-Ecore](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35.png?width=1772&height=385&name=HE_logo_fc-35.png "Health-Ecore")](https://health-ecore.com/?hsLang=en)

- [Home](https://health-ecore.com)
- [About us](https://health-ecore.com/about-us)
- [Team](https://health-ecore.com/team)
- [News](https://health-ecore.com/news)
- [Contact](https://health-ecore.com/contact)

Toggle Menu

Toggle Menu

- [Home](https://health-ecore.com)
- [About us](https://health-ecore.com/about-us)
- [Team](https://health-ecore.com/team)
- [News](https://health-ecore.com/news)
- [Contact](https://health-ecore.com/contact)

[Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all)

#### INVEST | INNOVATE | IMPLEMENT

## For sustainable health impact

**Healthcare is under pressure.** Rising demand and tightening budgets call for smarter investments. By optimizing the full health value chain from vitality and prevention to diagnosis, intervention, and monitoring, we can deliver higher-quality, more affordable care.

**Innovation is key.** It drives better outcomes, reduces costs, and supports a healthier, more productive society. But to succeed, we must strike the right balance: broad access, affordability, and fair rewards for innovation.

**The future of sustainable healthcare depends on integrated, scalable innovation. Let’s build it together.**

We work closely together with private as well as public parties, aiming at **sustainable impact** for our customers, the healthcare field, societies and economies.

We do this by applying a **holistic approach** based on a clear understanding of the healthcare field on macro, meso and micro level together with a unique combination of **scientific**, **entrepreneurial **and **policy **expertise.

![Impact figure website](https://health-ecore.com/hubfs/Impact%20figure%20website.svg)

## Our services

See what we can do for you.

![001-leadership](https://health-ecore.com/hs-fs/hubfs/001-leadership.png?width=100&height=100&name=001-leadership.png)

### Leadership

![006-group](https://health-ecore.com/hubfs/Custom%20icons/Bringing%20our%20health%20ecosystem%20together.svg)

###### Bringing our health ecosystem together

Involving the whole health ecosystem to focus on sustainable impact and improved health

![publicationsupdate](https://health-ecore.com/hs-fs/hubfs/publicationsupdate.png?width=80&height=80&name=publicationsupdate.png)

###### Evidence dissemination

Making an impact through scientific publications, presentations and general outreach

![006-group](https://health-ecore.com/hubfs/Custom%20icons/Training%20and%20education.svg)

###### Training & education

Focused on health outcomes, economics, policy and epidemiology

![002-strategy](https://health-ecore.com/hs-fs/hubfs/002-strategy.png?width=100&height=100&name=002-strategy.png)

### Strategic advice

![006-group](https://health-ecore.com/hubfs/Custom%20icons/005-market.png)

###### Strategic market access

Strategic advice during market access trajectories 

![006-group](https://health-ecore.com/hubfs/sustainable%20business%20and%20pricing%20models.svg)

###### Sustainable business & pricing models

Business and pricing models, price-lifecycle prediction and price negotiations

![006-group](https://health-ecore.com/hubfs/Custom%20icons/011-hospital.png)

###### Health policy & government affairs

Allignment of stakeholders towards implementation

![Health Economics and technology assessment](https://health-ecore.com/hubfs/Helath%20Economics%20and%20technology%20assessment.svg)

### Health Technology Assessment

![006-group](https://health-ecore.com/hubfs/Custom%20icons/006-group.png)

###### Holistic approach to HTA

Involving all stakeholders towards impactful market access trajectories

![006-group](https://health-ecore.com/hubfs/Custom%20icons/012-contribution.png)

###### Evidence synthesis and real-world insights

Insights into the clinical value, including therapeutic dossiers and systematic literature reviews

![006-group](https://health-ecore.com/hubfs/Custom%20icons/Economic%20and%20cost-effectiveness%20analysis.svg)

###### Economic and cost-effectiveness analyses

Health-economic model development, validation and adaptation

## Recent impact

Check out updates on the projects we work on.

<https://health-ecore.com/news/next-generation-covid-19-vaccine-mrna-1283-is-a-cost-effective-investment-for-older-and-high-risk-adults-in-the-netherlands?hsLang=en>

##### [Next-generation COVID-19 vaccine mRNA-1283 is a cost-effective investment for older and high-risk adults in the Netherlands](https://health-ecore.com/news/next-generation-covid-19-vaccine-mrna-1283-is-a-cost-effective-investment-for-older-and-high-risk-adults-in-the-netherlands?hsLang=en)

Simon van der Pol: Sep 21, 2026

 A new cost-effectiveness analysis finds that the next-generation vaccine mRNA-1283 could prevent thousands more hospitalisations and deaths than the vaccine currently used in the Netherlands, at a price the Dutch healthcare system can justify....

<https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands?hsLang=en>

##### [Adjuvanted influenza vaccine is a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands?hsLang=en)

Susan de Braak: Jul 3, 2026

 Replacing standard-dose with adjuvanted influenza vaccination in adults aged 60 and over, and in high-risk adults aged 50–59, could prevent hundreds of hospitalisations and deaths per season, at an incremental cost well within accepted Dutch...

<https://health-ecore.com/news/high-dose-influenza-vaccination-remains-a-cost-effective-investment-for-older-adults-in-the-netherlands?hsLang=en>

##### [High-dose influenza vaccination remains a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/news/high-dose-influenza-vaccination-remains-a-cost-effective-investment-for-older-adults-in-the-netherlands?hsLang=en)

Tanja Fens: Jun 24, 2026

 Updated health-economic evidence, drawing on data from more than 85 million individuals, confirms that switching from standard-dose to high-dose influenza vaccination would prevent thousands of hospitalisations each year, at a cost well within...

<https://health-ecore.com/news/a-coalition-of-the-doing-first-steps-toward-structural-data-exchange-in-healthcare?hsLang=en>

##### [A Coalition of the Doing: First Steps Toward Structural Data Exchange in Healthcare](https://health-ecore.com/news/a-coalition-of-the-doing-first-steps-toward-structural-data-exchange-in-healthcare?hsLang=en)

Muron van Abbema: Jun 11, 2026

 Despite a growing number of data infrastructures and increasing data initiatives, secondary use of data in healthcare remains structurally underutilised. For this reason, the first roundtable on data exchange in (pharmaceutical) healthcare was...

<https://health-ecore.com/news/what-delayed-rsv-vaccination-costs-the-netherlands?hsLang=en>

##### [What Delayed RSV Vaccination Is Costing the Netherlands](https://health-ecore.com/news/what-delayed-rsv-vaccination-costs-the-netherlands?hsLang=en)

Simon van der Pol: Jun 2, 2026

 Every winter, the Respiratory Syncytial Virus (RSV) fills hospital wards. Around 6,000 older adults are admitted with RSV infection in the Netherlands each year — a figure almost certainly conservative, given how rarely RSV diagnostics are applied...

<https://health-ecore.com/news/facilitating-investments-in-obesity-prevention-and-treatments-in-the-netherlands?hsLang=en>

##### [Facilitating Investments in Obesity Prevention and Treatments](https://health-ecore.com/news/facilitating-investments-in-obesity-prevention-and-treatments-in-the-netherlands?hsLang=en)

Bart Slob: May 13, 2026

 Health-Ecore colleagues Bart Slob and Lisa de Jong attended the European Congress of Obesity (ECO) in Istanbul and had the chance to present their research as a poster presentation called 'Facilitating investments in obesity prevention and...

## Our strategic partners

While we partner with many organizations in the health sector, both public and private, we have specific strategic partnerships with the following companies.

![digitalhealthlink](https://health-ecore.com/hs-fs/hubfs/project%20content/Other%20logos/digitalhealthlink.png?width=303&height=112&name=digitalhealthlink.png)

Digital Health Link enables secure, sustainable data exchange across healthcare systems. With their LinkinPin technology, they connect fragmented health data to support better insights, improved outcomes, and more affordable care—empowering a healthier society through data-driven innovation.

![Farminform-1](https://health-ecore.com/hs-fs/hubfs/project%20content/Other%20logos/Farminform-1.jpeg?width=303&height=202&name=Farminform-1.jpeg)

Farminform is a trusted data hub for the Dutch pharmaceutical sector. As an independent, not-for-profit data trust, they provide high-quality insights into medicine use and market trends, empowering healthcare providers, policymakers, and industry partners to make informed, data-driven decisions.

![medengine](https://health-ecore.com/hs-fs/hubfs/project%20content/Other%20logos/medengine.png?width=303&height=35&name=medengine.png)

MedEngine, with offices in Denmark, Finland, and Sweden, is a leading Nordic partner for the pharmaceutical industry, specializing in market access, real-world evidence, medical affairs, and commercial services. Combining deep expertise in data science, market access, and digital engagement, MedEngine develops tailored solutions that support every stage of the product lifecycle—from pre-launch to late-phase lifecycle management.

![PHARMA & HEALTH POLICY HUB-1](https://health-ecore.com/hs-fs/hubfs/project%20content/Other%20logos/PHARMA%20%26%20HEALTH%20POLICY%20HUB-1.png?width=303&height=81&name=PHARMA%20%26%20HEALTH%20POLICY%20HUB-1.png)

The Pharma & Health Policy Hub is a boutique consultancy with years of experience in international commercial, leadership, and policy domains within the pharmaceutical industry and healthcare. Paul van Hoof has an extensive international network within the biohpharmaceutical industry, civil society organizations, NGOs in healthcare policy, authorities, and patient advocacy groups.

![Logo-SensUR-Health-1-1](https://health-ecore.com/hs-fs/hubfs/Logo-SensUR-Health-1-1.png?width=303&height=139&name=Logo-SensUR-Health-1-1.png)

SensUR Health delivers rapid, point-of-care diagnostics that empower healthcare professionals with real-time insights from blood and urine samples. Their innovative technology supports faster decisions, better outcomes, and more personalized care.

### Interested in partnering with us?

Connect with us on our contact page or on our LinkedIn!

 

 

[Connect](https://health-ecore.com/contact?hsLang=en)

![HE\_Invest\_Innovate\_Implement-39](https://health-ecore.com/hs-fs/hubfs/HE_Invest_Innovate_Implement-39.png?width=500&height=36&name=HE_Invest_Innovate_Implement-39.png)

 

- [Contact details](https://health-ecore.com/contact)
- [Privacy policy](https://health-ecore.com/privacy-policy)
- [LinkedIn policy](https://health-ecore.com/linkedin-rules)

© 2026 Health-Ecore B.V.

[Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all) [GitHub](https://github.com/Health-Ecore)

Chamber of Commerce: 72059419 | Tax registration: NL 858968447 B01

Return to top